Daily Dx: Pelvic Mass

Reunion Neuroscience is enrolling patients in its phase 2 RECONNECT trial to assess a single-dose synthetic psychedelic to treat the depressive symptoms of PPD.

This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Kristina Adams-Waldorf, Professor in the Department of Obstetrics and Gynecology and Adjunct Professor in Global Health at the University of Washington (UW) School of Medicine in Seattle.

A recent study found that obese patients undergoing induction of labor experienced similar delivery times regardless of whether they received 50 μg or 25 μg of vaginal misoprostol, though multiparous patients showed faster delivery with the higher dosage.

This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Emily S. Miller, with Northwestern Medicine in Chicago.

According to a poster presented at ACOG 2024, use of the synthetic opioid buprenorphine depressed fetal breathing in biophysical profile assessments, but had no significant impact on other factors like amniotic fluid index or fetal tone.

New ACOG 2024 data suggest SARS-CoV-2 in the early stages of pregnancy can lead to a higher likelihood of preeclampsia, as well as more severe disease.